Sun Pharma's $11.

Sun Pharma's $11.75 Billion Organon Deal
Sun Pharmaceutical announced its largest acquisition ever, purchasing Organon for $11.75 billion. This major move signals a significant strategic shift away from the struggling US generics market, which faces intense pricing pressures and tariff volatility. The deal marks a pivot toward geographic diversification, allowing Sun Pharma to expand its portfolio beyond generic drugs into specialty pharmaceuticals and emerging markets. Investors responded positively, with Sun Pharma shares jumping nearly 7% on Monday following the announcement. The acquisition strengthens the company's position globally while reducing its dependence on the competitive and unprofitable US generics segment.